The companies first partnered in 2020 to develop a prescription digital therapeutic for schizophrenia. They said a treatment strategy for the condition “would benefit from a multi-product approach.”
Boehringer Ingelheim, Click Therapeutics expand partnership to develop prescription digital therapeutics
